Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2011, Article ID 318549, 8 pages
http://dx.doi.org/10.4061/2011/318549
Review Article

Benefits from Treatment and Control of Patients with Resistant Hypertension

1Veterans Affairs Medical Center, George Washington University, Washington, DC 20422, USA
2Veterans Affairs Medical Center, Georgetown University, Washington, DC 20422, USA
32nd Propaedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, 49 Konstantinoupoleos Street, 54643 Thessaloniki, Greece

Received 11 October 2010; Accepted 16 November 2010

Academic Editor: A. Gradman

Copyright © 2011 Michael Doumas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. A. Calhoun, D. Jones, S. Textor et al., “Resistant hypertension: diagnosis, evaluation and treatment,” Hypertension, vol. 117, pp. 510–526, 2008. View at Google Scholar
  2. P. A. Sarafidis and G. L. Bakris, “Resistant hypertension: an overview of evaluation and treatment,” Journal of the American College of Cardiology, vol. 52, no. 22, pp. 1749–1757, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. E. Pimenta, K. K. Gaddam, S. Oparil et al., “Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial,” Hypertension, vol. 54, no. 3, pp. 475–481, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. S. Douma, K. Petidis, M. Doumas et al., “Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study,” The Lancet, vol. 371, no. 9628, pp. 1921–1926, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. K. Nishizaka, M. A. Zaman, and D. A. Calhoun, “Efficacy of low-dose spironolactone in subjects with resistant hypertension,” American Journal of Hypertension, vol. 16, no. 11 I, pp. 925–930, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Mahmud, M. Mahgoub, M. Hall, and J. Feely, “Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?” American Journal of Hypertension, vol. 18, no. 12, pp. 1631–1635, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. Y. Sharabi, E. Adler, A. Shamis, N. Nussinovitch, A. Markovitz, and E. Grossman, “Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension,” American Journal of Hypertension, vol. 19, no. 7, pp. 750–755, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. F. De Souza, E. Muxfeldt, R. Fiszman, and G. Salles, “Efficacy of spironolactone therapy in patients with true resistant hypertension,” Hypertension, vol. 55, no. 1, pp. 147–152, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. D. A. Lane, S. Shah, and D. G. Beevers, “Low-dose spironolactone in the management of resistant hypertension: a surveillance study,” Journal of Hypertension, vol. 25, no. 4, pp. 891–894, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. N. Chapman, J. Dobson, S. Wilson et al., “Effect of spironolactone on blood pressure in subjects with resistant hypertension,” Hypertension, vol. 49, no. 4, pp. 839–845, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. H. K. Parthasarathy, K. Alhashmi, A. D. McMahon et al., “Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO,” Journal of Hypertension, vol. 28, no. 1, pp. 170–177, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. F. Volhard and T. Fahr, Die Brightsche Nierenkrankheit, Klinik, Pathologie und Atlas, Springer, Berlin, Germany, 1914.
  13. H. P. Wagener, “The retinitis of malignant hypertension,” Transactions of the American Ophthalmological Society, vol. 25, pp. 349–380, 1927. View at Google Scholar
  14. N. M. Keith, H. P. Wagener, and J. W. Kernohan, “The syndrome of malignant hypertension,” Archives of Internal Medicine, vol. 41, pp. 141–157, 1928. View at Google Scholar
  15. B. Hood, “Five and a half years experience of combination of antihypertensive drugs: main present difficulties,” in Hypotensive Drugs, M. Harington, Ed., pp. 135–148, Pergamon Press, New York, NY, USA, 1956. View at Google Scholar
  16. P. Kincaid-Smith, J. McMichael, and E. A. Murphy, “The clinical course and pathology of hypertension with papilloedema (malignant hypertension),” The Quarterly Journal of Medicine, vol. 27, no. 105, pp. 117–153, 1958. View at Google Scholar · View at Scopus
  17. M. F. Schottstaedt and M. Sokolow, “The natural history and course of hypertension with papilledema (Malignant Hypertension),” American Heart Journal, vol. 45, no. 3, pp. 331–362, 1953. View at Google Scholar · View at Scopus
  18. H. M. Perry Jr. and H. A. Schroeder, “The effect of treatment on mortality rates in severe hypertension; a comparison of medical and surgical regimens,” A.M.A. Archives of Internal Medicine, vol. 102, no. 3, pp. 418–425, 1958. View at Google Scholar · View at Scopus
  19. H. O. Mosenthal, “Clinical aspects of hypertension including malignant hypertension,” Bulletin of the New York Academy of Medicine, vol. 14, pp. 349–360, 1938. View at Google Scholar
  20. C. P. Howard, “The diagnosis and treatment of malignant hypertension,” Canadian Medical Association Journal, vol. 32, pp. 621–624, 1935. View at Google Scholar
  21. F. O. Simpson and F. H. Smirk, “The treatment of malignant hypertension,” The American Journal of Cardiology, vol. 9, no. 6, pp. 868–873, 1962. View at Google Scholar · View at Scopus
  22. W. Grobin, “Malignant hypertension and its treatment,” Canadian Medical Association Journal, vol. 82, pp. 600–601, 1960. View at Google Scholar
  23. C. J. Bulpitt, “Prognosis of treated hypertension 1951–1981,” British Journal of Clinical Pharmacology, vol. 13, no. 1, pp. 73–79, 1982. View at Google Scholar · View at Scopus
  24. B. Greenwood, “The origins of sympathectomy,” Medical History, vol. 11, no. 2, pp. 165–169, 1967. View at Google Scholar · View at Scopus
  25. N. M. Keith, H. P. Wagener, and N. W. Barker, “Some different types of essential hypertension: their course and prognosis,” American Journal of the Medical Sciences, vol. 268, no. 6, pp. 336–345, 1974. View at Google Scholar · View at Scopus
  26. M. M. Peet, W. W. Woods, and B. Braden, “The surgical treatment of hypertension,” The Journal of the American Medical Association, vol. 115, pp. 1875–1885, 1940. View at Google Scholar
  27. I. H. Page and G. J. Heuer, “A surgical treatment of essential hypertension,” The Journal of Clinical Investigation, vol. 14, pp. 22–26, 1935. View at Google Scholar
  28. R. H. Smithwick, “Surgical treatment of hypertension,” The American Journal of Medicine, vol. 4, no. 5, pp. 744–759, 1948. View at Google Scholar · View at Scopus
  29. E. M. Isberg and M. M. Peet, “The influence of supradiaphragmatic splanchnicectomy on the heart in hypertension,” American Heart Journal, vol. 35, no. 4, pp. 567–583, 1948. View at Google Scholar · View at Scopus
  30. E. V. Allen, “Sympathectomy for essential hypertension,” Circulation, vol. 6, no. 1, pp. 131–140, 1952. View at Google Scholar · View at Scopus
  31. G. P. Whitelaw, D. Kinsey, and R. H. Smithwick, “Factors influencing the choice of treatment in essential hypertension. Surgical, medical or a combination of both,” The American Journal of Surgery, vol. 107, no. 1, pp. 220–231, 1964. View at Google Scholar · View at Scopus
  32. S. Hammarström and P. Bechgaard, “Prognosis in arterial hypertension. Comparison between 251 patients after sympathectomy and a selected series of 435 non-operated patients,” The American Journal of Medicine, vol. 8, no. 1, pp. 53–56, 1950. View at Google Scholar · View at Scopus
  33. J. A. Evans, “The place of splanchnicectomy in the treatment of hypertension,” Canadian Medical Association journal, vol. 64, no. 1, pp. 47–50, 1951. View at Google Scholar · View at Scopus
  34. J. W. Hinton, “End results of thoracolumbar sympathectomy for advanced essential hypertension,” California Medicine, vol. 70, no. 4, pp. 282–287, 1949. View at Google Scholar
  35. K. S. Grimson, E. S. Orgain, and B. Anderson, “Results of treatment of patients with hypertension by total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy,” Annals of Surgery, vol. 129, pp. 850–871, 1949. View at Google Scholar
  36. J. C. Harland and F. d'Abreu, “Lumbodorsal sympathectomy in severe hypertension,” British Medical Journal, vol. 1, pp. 1019–1024, 1949. View at Google Scholar
  37. S. M. Chris, “Sympathectomy for hypertension,” British medical journal, vol. 1, no. 4708, pp. 665–670, 1951. View at Google Scholar · View at Scopus
  38. M. Doumas, C. Faselis, and V. Papademetriou, “Renal sympathetic denervation and systemic hypertension,” American Journal of Cardiology, vol. 105, no. 4, pp. 570–576, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. R. H. Smithwick and J. E. Thompson, “Splanchnicectomy for essential hypertension; results in 1,266 cases,” Journal of the American Medical Association, vol. 152, no. 16, pp. 1501–1504, 1953. View at Google Scholar · View at Scopus
  40. M. Harington, P. Kincaid-Smith, and J. McMichael, “Results of treatment in malignant hypertension: a seven-year experience in 94 cases,” British Medical Journal, vol. 2, no. 5158, pp. 969–980, 1959. View at Google Scholar · View at Scopus
  41. W. Goldring and H. Chasis, “Antihypertensive drug therapy,” in Controversy in Internal Medicine, F. J. Ingelfinger, A. S. Relman, and M. Finland, Eds., pp. 83–91, WB Saunders, Philadelfia, Pa, USA, 1966. View at Google Scholar
  42. W. Osler, “Am address on high blood pressure: its associations, advantages, and disadvantages,” British Medical Journal, vol. 2, pp. 1173–1177, 1912. View at Google Scholar
  43. Veterans Administration Cooperative Study Group on Antihypertensive Agents, “Effects of treatment on morbidity and mortality in hypertension: results in patients with diastolic blood pressures averaging 115-129 mmHg,” The Journal of the American Medical Association, vol. 202, pp. 116–122, 1967. View at Google Scholar
  44. R. Reader, G. E. Bauer, and A. E. Doyle, “The Australian therapeutic trial in mild hypertension. Report by the Management Committee,” The Lancet, vol. 1, no. 8181, pp. 1261–1267, 1980. View at Google Scholar · View at Scopus
  45. P. I. Korner, G. E. Bauer, and A. E. Doyle, “Untreated mild hypertension. A report by the management committee of the Australian therapeutic trial in mild hypertension,” The Lancet, vol. 1, no. 8265, pp. 185–191, 1982. View at Google Scholar · View at Scopus
  46. The Management Committee of the Australian National Blood Pressure Study, “Prognostic factors in the treatment of mild hypertension,” Circulation, vol. 69, pp. 668–676, 1984. View at Google Scholar
  47. H. Isaksson and J. Ostergren, “Prognosis in therapy-resistant hypertension,” Journal of Internal Medicine, vol. 236, no. 6, pp. 643–649, 1994. View at Google Scholar · View at Scopus
  48. J. Redon, C. Campos, M. L. Narciso, J. L. Rodicio, J. M. Pascual, and L. M. Ruilope, “Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study,” Hypertension, vol. 31, no. 2, pp. 712–718, 1998. View at Google Scholar · View at Scopus
  49. S. D. Pierdomenico, D. Lapenna, A. Bucci et al., “Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension,” American Journal of Hypertension, vol. 18, no. 11, pp. 1422–1428, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. G. F. Salles, C. R. L. Cardoso, and E. S. Muxfeldt, “Prognostic influence of office and ambulatory blood pressures in resistant hypertension,” Archives of Internal Medicine, vol. 168, no. 21, pp. 2340–2346, 2008. View at Google Scholar · View at Scopus
  51. E. S. Muxfeldt, C. R. L. Cardoso, and G. F. Salles, “Prognostic value of nocturnal blood pressure reduction in resistant hypertension,” Archives of Internal Medicine, vol. 169, no. 9, pp. 874–880, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. E. S. Muxfeldt, C. R. L. Cardoso, V. B. Dias, A. C. M. Nascimento, and G. F. Salles, “Prognostic impact of the ambulatory arterial stiffness index in resistant hypertension,” Journal of Hypertension, vol. 28, no. 7, pp. 1547–1553, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. G. F. Salles, C. R. L. Cardoso, R. Fiszman, and E. S. Muxfeldt, “Prognostic significance of baseline and serial changes in electrocardiographic strain pattern in resistant hypertension,” Journal of Hypertension, vol. 28, pp. 1715–1723, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. G. F. Salles, C. R. L. Cardoso, and E. S. Muxfeldt, “Prognostic value of ventricular repolarization prolongation in resistant hypertension: a prospective cohort study,” Journal of Hypertension, vol. 27, no. 5, pp. 1094–1101, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. M. M. F. Magnanini, A. D. R. Nogueira, M. S. Carvalho, and K. V. Bloch, “Ambulatory blood pressure monitoring and cardiovascular risk in resistant hypertensive women,” Arquivos Brasileiros de Cardiologia, vol. 92, no. 6, pp. 448–489, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Benetos, F. Thomas, K. Bean, S. Gautier, H. Smulyan, and L. Guize, “Prognostic value of systolic and diastolic blood pressure in treated hypertensive men,” Archives of Internal Medicine, vol. 162, no. 5, pp. 577–581, 2002. View at Google Scholar · View at Scopus
  57. H. M. Perry, J. P. Miller, J. R. Fornoff et al., “Early predictors of 15-year end-stage renal disease in hypertensive patients,” Hypertension, vol. 25, no. 4 I, pp. 587–594, 1995. View at Google Scholar · View at Scopus
  58. B. Dahlöf, P. S. Sever, N. R. Poulter et al., “Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial,” The Lancet, vol. 366, no. 9489, pp. 895–906, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. K. Jamerson, M. A. Weber, G. L. Bakris et al., “Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients,” The New England Journal of Medicine, vol. 359, no. 23, pp. 2417–2428, 2008. View at Publisher · View at Google Scholar · View at PubMed
  60. C. D. Furberg, J. T. Wright Jr., B. R. Davis et al., “Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT),” Journal of the American Medical Association, vol. 288, no. 23, pp. 2981–2997, 2002. View at Publisher · View at Google Scholar
  61. M. A. Weber, H. Black, G. Bakris et al., “A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 374, no. 9699, pp. 1423–1431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. G. L. Bakris, L. H. Lindholm, H. R. Black et al., “Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial,” Hypertension, vol. 56, no. 5, pp. 824–830, 2010. View at Publisher · View at Google Scholar · View at PubMed
  63. I. J. M. Scheffers, A. A. Kroon, J. Schmidli et al., “Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study,” Journal of the American College of Cardiology, vol. 56, no. 15, pp. 1254–1258, 2010. View at Publisher · View at Google Scholar · View at PubMed
  64. H. Krum, M. Schlaich, R. Whitbourn et al., “Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study,” The Lancet, vol. 373, no. 9671, pp. 1275–1281, 2009. View at Publisher · View at Google Scholar · View at Scopus